SCHEMBL6370442

SCHEMBL6370442

CN(C)CCCNC(=O)c1ccc(-c2n[nH]c3cc(Nc4ccccc4Cl)ccc23)cc1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 12/20 0.90
MAPK10 P53779 10/20 0.90
MAPK14 Q16539 10/20 0.90
AURKA O14965 1/20 0.49
AURKB Q96GD4 1/20 0.49
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TRPA1 O75762 1/20 0.44
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
WNT1 P04628 1/20 0.43
DYRK1A Q13627 1/20 0.43
MEN1 O00255 1/20 0.43
MITF O75030 1/20 0.43
POLB P06746 1/20 0.43
RAD52 P43351 1/20 0.43
KMT2A Q03164 1/20 0.43
FYN P06241 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6422935 0.95 MAPK8 (1.00) MAPK8MAPK10MAPK14AURKAAURKB
SCHEMBL6375883 0.92 MAPK8 (0.90) MAPK8MAPK10MAPK14AURKAAURKB
SCHEMBL6371425 0.86 MAPK8 (1.00) MAPK8MAPK10MAPK14AURKAAURKB
SCHEMBL6370407 0.85 MAPK8 (0.73) MAPK8MAPK10MAPK14KDM4EALDH1A1
SCHEMBL6377006 0.84 MAPK8 (0.81) MAPK8MAPK10MAPK14
SCHEMBL6371920 0.83 MAPK10 (0.74) MAPK8MAPK10MAPK14
SCHEMBL6376886 0.83 MAPK10 (0.71) MAPK8MAPK10MAPK14
SCHEMBL12656626 0.81 MAPK8 (0.75) MAPK8MAPK10MAPK14AURKAAURKB
SCHEMBL6369600 0.80 MAPK10 (0.81) MAPK8MAPK10MAPK14
SCHEMBL6370349 0.80 MAPK8 (0.78) MAPK8MAPK10MAPK14AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US claimed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP claimed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO claimed
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113370-A1 Therapeutic substituted indazole derivatives NR4A3, CBR3, NR3C2 MAPK8 1582/4885MAPK10 2059/4885MAPK14 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.